PURPOSE: Trachoma remains a leading cause of blindness. Determining the most effective antibiotic treatment strategy is essential for the success of country-based trachoma control programs. METHODS: Baseline and 2-month follow-up examinations were performed in a trachoma-hyperendemic village. All residents were offered azithromycin for trachoma after baseline was determined. Infection with Chlamydia trachomatis and chlamydial load were determined by PCR. Clinical trachoma status was evaluated. A high chlamydial load was defined as a higher than median chlamydial load among those with infection. Risk factors were examined in multiple logistic regression models. Associations are presented as odds ratios and 95% confidence intervals. RESULTS: At baseline, 57% of participants were infected with C. trachomatis. Although clinical trachoma correlated with infection, 23% of participants with high chlamydial loads showed no clinical signs. Adults represented only 10% of the population with high loads. Treatment significantly decreased the proportion positive in the community and the load in the community. However, 27% of individuals with high loads at baseline who received treatment also were infected at 2 months. Of those, 93% with high loads at 2 months were aged < or =10 years. CONCLUSIONS: Although most of the chlamydial load in this community resided in children, 10% of the high load resided in adults, most of whom did not have follicular trachoma and in whom the infection would be missed under treatment strategies that focus on clinical disease or children. These data support a mass treatment strategy for hyperendemic communities, at least as a first approach. In addition, treatment of children age < or =2 years should be reexamined, as >30% with high loads at baseline remained infected at 2 months, despite monitored treatment according to weight.
PURPOSE: Trachoma remains a leading cause of blindness. Determining the most effective antibiotic treatment strategy is essential for the success of country-based trachoma control programs. METHODS: Baseline and 2-month follow-up examinations were performed in a trachoma-hyperendemic village. All residents were offered azithromycin for trachoma after baseline was determined. Infection with Chlamydia trachomatis and chlamydial load were determined by PCR. Clinical trachoma status was evaluated. A high chlamydial load was defined as a higher than median chlamydial load among those with infection. Risk factors were examined in multiple logistic regression models. Associations are presented as odds ratios and 95% confidence intervals. RESULTS: At baseline, 57% of participants were infected with C. trachomatis. Although clinical trachoma correlated with infection, 23% of participants with high chlamydial loads showed no clinical signs. Adults represented only 10% of the population with high loads. Treatment significantly decreased the proportion positive in the community and the load in the community. However, 27% of individuals with high loads at baseline who received treatment also were infected at 2 months. Of those, 93% with high loads at 2 months were aged < or =10 years. CONCLUSIONS: Although most of the chlamydial load in this community resided in children, 10% of the high load resided in adults, most of whom did not have follicular trachoma and in whom the infection would be missed under treatment strategies that focus on clinical disease or children. These data support a mass treatment strategy for hyperendemic communities, at least as a first approach. In addition, treatment of children age < or =2 years should be reexamined, as >30% with high loads at baseline remained infected at 2 months, despite monitored treatment according to weight.
Authors: J Schachter; S K West; D Mabey; C R Dawson; L Bobo; R Bailey; S Vitale; T C Quinn; A Sheta; S Sallam; H Mkocha; D Mabey; H Faal Journal: Lancet Date: 1999-08-21 Impact factor: 79.321
Authors: Muluken Melese; Jaya Devi Chidambaram; Wondu Alemayehu; David Chung Lee; Elizabeth H Yi; Vicky Cevallos; Zhaoxia Zhou; Cathy Donnellan; Michael Saidel; John P Whitcher; Bruce D Gaynor; Thomas M Lietman Journal: JAMA Date: 2004-08-11 Impact factor: 56.272
Authors: Beatriz Muñoz; Anthony W Solomon; James Zingeser; Rachel Barwick; Matthew Burton; Robin Bailey; David Mabey; Allen Foster; Sheila K West Journal: Invest Ophthalmol Vis Sci Date: 2003-04 Impact factor: 4.799
Authors: Matthew J Burton; Martin J Holland; Nkoyo Faal; Esther A N Aryee; Neal D E Alexander; Momodou Bah; Hannah Faal; Sheila K West; Allen Foster; Gordon J Johnson; David C W Mabey; Robin L Bailey Journal: Invest Ophthalmol Vis Sci Date: 2003-10 Impact factor: 4.799
Authors: Joseph P Sheehan; Sintayehu Gebresillasie; Ayalew Shiferaw; Solomon Aragie; Zerihun Tadesse; Demelash Tadesse; Thanapong Somkijrungroj; Nicole E Stoller; E Kelly Callahan; Paul M Emerson; Thomas M Lietman; Jeremy D Keenan Journal: Am J Trop Med Hyg Date: 2018-05-24 Impact factor: 2.345
Authors: Vicky Cevallos; John P Whitcher; Muluken Melese; Wondu Alemayehu; Elizabeth Yi; Jaya D Chidambaram; Scott Lee; Harsha Reddy; Bruce D Gaynor; Thomas M Lietman; Jeremy D Keenan Journal: Invest Ophthalmol Vis Sci Date: 2012-08-07 Impact factor: 4.799
Authors: Sheila K West; Dianne Stare; Harran Mkocha; Beatriz Munoz; Charlotte Gaydos; Thomas C Quinn Journal: Invest Ophthalmol Vis Sci Date: 2011-07-29 Impact factor: 4.799
Authors: Manoj Gambhir; Maria-Gloria Basáñez; Matthew J Burton; Anthony W Solomon; Robin L Bailey; Martin J Holland; Isobel M Blake; Christl A Donnelly; Ibrahim Jabr; David C Mabey; Nicholas C Grassly Journal: PLoS Negl Trop Dis Date: 2009-06-16